



## **P-169 - Influence of radiolysis on astatine-211 chemistry**

Mohammad Ghalei, Parastoo Mahdi Khoshouei, Johan Vandenborre, François Guérard, Guillaume Blain, Mojtaba Zarei, Ferid Haddad, Massoud Fattahi

### **► To cite this version:**

Mohammad Ghalei, Parastoo Mahdi Khoshouei, Johan Vandenborre, François Guérard, Guillaume Blain, et al.. P-169 - Influence of radiolysis on astatine-211 chemistry. International symposium of radiopharmaceutical sciences, May 2022, Nantes, France. inserm-03821660

**HAL Id: inserm-03821660**

**<https://inserm.hal.science/inserm-03821660>**

Submitted on 19 Oct 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

team has set up a radiosynthesis of  $^{64}\text{Cu}$ -radiolabeled compound whose process and operators were qualified at the aseptic level by the realization of media fill test and bioburden. The outsourced sterility analyses have also been qualified. The entire production is based on a robust chain between independent departments: Quality Assurance (QA), Radiopharmacy (production), Quality Control (QC),  $^{64}\text{Cu}$  raw material production and also support departments (radiosafety department, facility management). Therefore, the QA system has enabled the implementation of an efficient electronic document management system and has ensured the follow-up of operators' training and equipment qualifications. QC has played a major role in the management of the raw material circuit, filling items and finished product controls. The release by the radiopharmacist is thus allowed to be in optimal conditions before administration to a patient.

All the steps described above will be detailed in order to propose a global review of all the elements that have to be implemented to provide a radiopharmaceutical in Phase I clinical trial according to GMP industrial standards.

#### References:

- [1] Bourgeois M, Rajerison H, Guerard F, Mougin-Degraef M, Barbet J, Michel N, et al. Contribution of  $[^{64}\text{Cu}]\text{-ATSM}$  PET in molecular imaging of tumour hypoxia compared to classical  $[^{18}\text{F}]\text{-MISO}$ —a selected review. *Nucl Med Rev East Eur*. 2011;14(2):90–5.
- [2] Vidal A, Bourdeau C, Frindel M, Garcia T, Haddad F, Faivre-Chauvet A, et al. ARRONAX Cyclotron: Setting up of In-House Hospital Radiopharmacy. *Biomed Res Int*. 2020;2020:1572841.

#### P-169

##### Influence of radiolysis on astatine-211 chemistry

**Mohammad Chalei**<sup>1</sup>, Parastoo Mahdi Khoshouei<sup>2</sup>, Johan Vandenborre<sup>3</sup>, Francois Guérard<sup>4</sup>, Guillaume Blain<sup>3</sup>, Mojtaba Zarei, Ferid Haddad<sup>5</sup>, Massoud Fattahi<sup>6</sup>

<sup>1</sup>Subatech, France, <sup>2</sup>Subatech, Iran, <sup>3</sup>Subatech and Arronax, France,

<sup>4</sup>Nantes Université, France, <sup>5</sup>GIP ARRONAX, France, <sup>6</sup>Subatech and Arronax

**Objective:** Astatine-211 is one of the good candidate among radioisotopes that can be used for targeted alpha therapy. Its half-life (7.2 h) makes it possible to label it with different kinds of molecules with different size.  $^{211}\text{At}$  alpha emitting cause auto radiolysis which influence its chemical stability and oxidation state. That is why radiolabeling of this radioisotope is complicated. This study aims to address the impact of radiolysis on astatine chemistry.

**Methods:** For this purpose; first, the pH of chloroform medium was measured during the  $^{211}\text{At}$  extraction and second, the medium was irradiated by  $\gamma$ -ray. At the end of irradiation for second time, the pH was determined by measuring HCl chemical yield obtained during the radiolysis ( $G_{\text{HCl}}$ ). In this study, we investigated the amounts of produced HCl under  $\gamma$  radiations in presence and absence of oxygen at low doses of irradiation. The latter one allowing to be close to the dose rate corresponding to the real conditions of exposure of chloroform when performing  $^{211}\text{At}$ - radiopharmaceuticals for pre-clinical development.

**Results:** Figure 1 is shown the obtained data in this study. The  $G_{\text{HCl}}$  is 1.46 folds higher in aerated medium. According to our results at low doses ( $< 500$  Gy) a small difference is observed for the radiolytic yield of acids with and without air. This difference is grown when the dose is increased which means that oxygen can react with  $\text{CHCl}_3$  in presence of ionizing radiation to form HCl [1].

**Conclusion:** The amount of HCl follows a linear behavior. In the low dose range ( $< 3\text{ kGy}$ ), the trichlorohydroperoxymethane ( $\text{Cl}_3\text{COOH}$ ) production by chloroform reaction with  $\text{O}_2$ , must be taken into account for the mechanisms of HCl production. In fact, with the G-value determined in this work we have calculated the theoretical pH value in the Chloroform/Astatine solution ( $\text{pH} = 2.3$ ) close




Figure 1. Experimental G-yield values of HCl, produced during irradiation of  $\text{CHCl}_3$  in aerated (red spots) and oxygen free (blue ones) atmospheres by  $^{137}\text{Cs}$ -source irradiator  $E_\gamma = 0.667$  MeV, Dose Rate =  $7.9$  Gy/min, Total Dose =  $2580$  Gy.

to the one measured in the real Astatine complexation/extraction process ( $\text{pH} = 1.5$ ). Moreover, synthesis  $^{211}\text{At}$  radiopharmaceuticals such as SAB (N-succinimidyl 3- $^{211}\text{At}$ -astatobenzoate) is suffered from chemical decomposition [2] and formation of HCl by radiolysis may explain this problem. Our results may also explain why different species of  $^{211}\text{At}$  exist in chloroform at the same time [3]. We recommend a washing of astatine solution with water before use for radiochemistry.

**Acknowledgment:** This work has been supported in part by a grant from the French National Agency for Research called "Investissements d'Avenir", IRON Labex no. ANR-11-LABX-0018-01 and Equipex ArronaxPlus n°ANR-11-EQPX-0004 and ISITE NEXT n°ANR-16-IDEX-0007. The authors would like to express their gratitude for the ARRONAX facility teams for their technical support.

#### References:

- [1] Schulte, J.W., Suttle, J.F., Wilhelm, R., 1953. Chemical Effects Produced in Chloroform by  $\gamma$ -Rays1. *Journal of the American Chemical Society* 75, 2222–2227
- [2] Pozzi, O.R., Zalutsky, M.R., 2017. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for  $^{211}\text{At}$  labeling at high activities and radiation doses of  $^{211}\text{At}$   $\alpha$ -particles. *Nuclear Medicine and Biology* 46, 43–49
- [3] Aneheim, E., Palm, S., Jensen, H., Ekberg, C., Albertsson, P., Lindegren, S., 2019. Towards elucidating the radiochemistry of astatine – Behavior in chloroform. *Scientific Reports* 9, 15900

#### P-170

##### A study to obtain a highly reproducible radiochemical yield (RCY) in the PSMA-11 radiolabeling

**Antonella Iudicello**, Giacomo Maria Lima, Lucia Massi, Stefano Panareo  
<sup>1</sup>Policlinico, Italy

**Objectives:** A highly reproducible radiochemical yield (RCY) is an important parameter for the planning and optimization of clinical routine activity.

It is known that in the case of radiometallation of PSMA-11, the presence of metal ion contaminants in the peptide precursor causes a decrease of the  $[^{68}\text{Ga}]\text{Ga-PSMA-11}$  radiochemical yield because the Fe (III) competes with gallium-68 during the complexation reaction with the chelator.

In this study, we present the data obtained in our institute preparing the solution of PSMA-11 synthesis precursor following various methods in order to obtain a high and over-time reproducible % RCY.

**Methods:** According to European Pharmacopoeia (Ph. Eur.) Monograph "Gallium ( $^{68}\text{Ga}$ ) PSMA-11 injection", which prescribes to use of a maximum of  $30 \mu\text{g}$  of PSMA-11 for  $[^{68}\text{Ga}]\text{Ga-PSMA-11}$